Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Patients Previously Treated With AUTO CAR T Cell Therapy
NCT03628612Phase 2Enrolling by invitation
- Sponsor
- Autolus Therapeutics plc
- Start
- Aug 2018
- Primary completion
- Jul 2043
- Modality
- Allogeneic CAR-T, HLA-matched TCR-T, HLA-independent TCR-T
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial in multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL) and 1 more, sponsored by Autolus Therapeutics plc. Primary endpoint: Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapy at 15 years. Started Aug 2018; status: enrolling by invitation.
02
Conditions
multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)acute lymphoblastic leukemia (ALL)T-cell lymphoma
Beyond the preview
Go deeper on NCT03628612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628612.